Stocks Health care LYEL
NASDAQ · Health careLyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. brought in $15K of revenue over the twelve months to September 30, 2026, down 63.4% from a year earlier. It posted a net loss of $255.2M. In fiscal 2025 capital spending exceeded operating cash flow by $150.8M. At September 30, 2026 it held $92.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Lyell Immunopharma, Inc.
- Net worth
- Lyell Immunopharma, Inc. has a market value (market cap) of $410.5M at the latest share price, and shareholders' equity of $192.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $36K (-41.0% year on year), with a net loss of $274.4M. Over the 12 months to September 30, 2026: revenue $15K, net loss $255.2M.
- Cash flow
- In fiscal 2025 operations used $150M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lyell Immunopharma, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Lyell Immunopharma, Inc. does
Lyell Immunopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LYEL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $36K | -$274.4M | -$16.06 | -$150.8M |
| 2024 | $61K | -$343M | -$26.23 | -$162.9M |
| 2023 | $130K | -$234.6M | -$18.70 | -$166.4M |
| 2022 | $84.7M | -$183.1M | -$14.88 | -$193.8M |
| 2021 | $10.7M | -$250.2M | -$37.00 | -$191.8M |
| 2021 | $7.8M | -$204.5M | -$315.49 | -$212.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LYEL ranks in Health care
Latest SEC filings
What Lyell Immunopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 80% to $3K versus the same quarter last year; diluted EPS -$1.86 versus -$2.13.
- November 4, 2026
- November 4, 2026
- September 10, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 50% to $4K versus the same quarter last year; diluted EPS -$1.92 versus -$2.89.
- August 6, 2026
- July 13, 2026
- June 18, 2026Passive stake changed SCHEDULE 13G/A
- June 15, 2026
Insider trades
What the people running Lyell Immunopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $50M and sold $197K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | ARCH Venture Fund XIII, L.P.10% owner | Boughtindirect | 2,321,262 | $25M |
| November 4, 2026 | ARCH Venture Partners IX, LLC10% owner | Boughtindirect | 2,321,262 | $25M |
| October 12, 2026 | Aguirre Jarrad MattieuChief Medical Officer | Sold | 422 | $3.6K |
| September 10, 2026 | Shook DavidChief Medical Officer | Sold | 500 | $6.4K |
| August 21, 2026 | Seely LynnPresident and CEO, Director | Sold | 9,589 | $149K |
| August 21, 2026 | Hill Stephen J.Chief Operating Officer | Sold | 989 | $15.4K |
| August 21, 2026 | Lee Gary K.Chief Scientific Officer | Sold | 1,457 | $22.6K |
| August 10, 2026 | Seely LynnPresident and CEO, Director | Sold | 390 | $5.6K |
Who owns LYEL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARCH Venture Fund IX, L.P.13G, passive with 13 related filers | 13.9% | May 15, 2026 |
| Innovative Cellular Therapeutics Holdings Limited13G, passive | 12.3% | June 18, 2026 |
| Euler Fund, L.P.13G, passive with 2 related filers | 6.71% | April 21, 2026 |
| Explore Investments LLC13G, passive with 1 related filers | 6.6% | May 8, 2026 |
| Gates Frontier, LLC13G, passive with 1 related filers | 5.6% | August 1, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 87 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| ARCH Venture Management, LLC | 3,247,162 | 0 |
| GSK plc | 1,512,659 | 0 |
| Vanguard Capital Management LLC | 786,774 | +68,619 |
| Orland Properties Ltd | 754,698 | 0 |
| BlackRock, Inc. | 724,342 | +532,522 |
| Decheng Capital LLC | 692,050 | 0 |
| Almitas Capital LLC | 581,407 | +3,600 |
| Foresite Capital Management V, LLC | 476,386 | -692 |
| Millennium Management LLC | 367,473 | -91,432 |
| Opaleye Management Inc. | 344,025 | +264,928 |
| venBio Partners LLC | 337,697 | 0 |
| Geode Capital Management, LLC | 310,636 | +143,656 |
| Alphabet Inc. | 293,256 | 0 |
| State Street Corp | 185,322 | +112,800 |
| HSG Holding Ltd | 152,299 | 0 |
| Renaissance Technologies LLC | 130,190 | +13,779 |
| Northern Trust Corp | 118,500 | +88,220 |
| Qube Research & Technologies Ltd | 110,531 | +55,421 |
| Charles Schwab Investment Management Inc | 107,570 | +21,599 |
| Marshall Wace, Llp | 106,300 | -42,216 |
Insiders
9 insiders reported holding 10,422,574 shares in total, about $174.6M at the last price.
| Holder | Shares |
|---|---|
| ARCH Venture Partners IX, LLC10% owner | 3,747,7903,747,790 held indirectly |
| ARCH Venture Fund XIII, L.P.10% owner | 3,747,7903,747,790 held indirectly |
| Innovative Cellular Therapeutics Holdings Ltd10% owner | 2,774,980 |
| Seely LynnPresident and CEO, Director | 63,899 |
| Shook DavidChief Medical Officer | 20,423 |
| Aguirre Jarrad MattieuChief Medical Officer | 19,857 |
| Hill Stephen J.Chief Operating Officer | 16,816 |
| Lee Gary K.Chief Scientific Officer | 16,220 |
| Bulis Veronica SanchezVP, Corporate Controller | 14,799 |
Questions about LYEL
What does Lyell Immunopharma, Inc. do?
Lyell Immunopharma, Inc. is a company in the Health care sector, listed on NASDAQ as LYEL. Its shares trade on NASDAQ under the ticker LYEL.
What is Lyell Immunopharma, Inc.'s net worth?
Lyell Immunopharma, Inc. has a market value (market cap) of $410.5M at the latest share price, and shareholders' equity of $192.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lyell Immunopharma, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $255.2M on revenue of $15K.
How much revenue does Lyell Immunopharma, Inc. make?
Over the twelve months to September 30, 2026 Lyell Immunopharma, Inc. reported revenue of $15K. That is 63.4% less than a year earlier.
When did Lyell Immunopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Lyell Immunopharma, Inc.'s next earnings report?
Lyell Immunopharma, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LYEL with
Follow LYEL
Get an email when Lyell Immunopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lyell Immunopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.